Sensei Biotherapeutics Merges with Faeth Therapeutics, Secures $200M Funding

The merger gives Sensei a new lead cancer drug candidate and a path forward after considering winding down the company.

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. But the biotech has found a new lease on life—and a new lead drug—via a merger with Faeth Therapeutics. Shareholders of privately owned Faeth will own 40.8% of the merged company, while Sensei's current shareholders will own 4.9%. The rest will be owned by investors that participated in a $200 million private placement.

Why it matters

The merger and financing provide a critical lifeline for Sensei, which was considering shutting down just months ago due to dwindling cash reserves and a shrinking pipeline. The new lead drug candidate, PIKTOR, is a combination of two PI3K/AKT/mTOR pathway inhibitors that Sensei believes can achieve more complete pathway suppression with improved tolerability compared to single-node inhibitors.

The details

The enlarged Sensei will be focused on a phase 2 study of PIKTOR in second-line advanced endometrial cancer as well as a phase 1b trial in HR+/HER2- advanced breast cancer. The $200 million private placement will fund these studies, with top-line phase 2 data in endometrial cancer and the launch of the phase 1b breast cancer trial expected by the end of 2026.

  • Sensei was considering winding down the company a couple of months ago.
  • Sensei went public in a $133 million IPO in 2021.
  • Sensei had previously trimmed its workforce by 46% and closed its Rockville, Maryland research site in a decision linked to keeping funds flowing to its solnerstotug program.
  • By the end of last year, Sensei was down to $25 million in cash and equivalents.

The players

Sensei Biotherapeutics

A biotech company that has found a new lease on life through a merger with Faeth Therapeutics and a $200 million private placement.

Faeth Therapeutics

A privately owned biotech company that is merging with Sensei Biotherapeutics, with Faeth's shareholders owning 40.8% of the combined company.

Anand Parikh

The co-founder of Faeth Therapeutics, who will now become the Chief Operating Officer of the merged Sensei Biotherapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability.”

— Anand Parikh, Co-founder, Faeth Therapeutics (fiercebiotech.com)

“This financing takes us through topline phase 2 data in that population and advances the phase 1b breast cancer program.”

— Anand Parikh, Co-founder, Faeth Therapeutics (fiercebiotech.com)

What’s next

The enlarged Sensei will be focused on a phase 2 study of PIKTOR in second-line advanced endometrial cancer as well as gearing up for a phase 1b trial in HR+/HER2- advanced breast cancer. Both the phase 2 readout and launch of the phase 1b study are expected to occur before the end of 2026.

The takeaway

The merger and financing deal marks a critical turnaround for Sensei Biotherapeutics, which was on the brink of shutting down just months ago. The new lead drug candidate, PIKTOR, and the $200 million in funding provide Sensei with a path forward as it seeks to advance the drug through late-stage clinical trials in endometrial and breast cancer.